Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTER: Elranatamab + Daratumumab vs ASCT + Lenalidomide/Daratumumab in Newly Diagnosed Multiple Myeloma
NCT06974786Phase 2Recruiting
- Sponsor
- SCRI Development Innovations
- Start
- Aug 2025
- Primary completion
- Nov 2032
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started Aug 2025; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06974786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974786.